- According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%.
- According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial.
- Results showed that 546 patients in the standard of care group died within 28 days, compared to 513 patients in the baricitinib group who died where they were also given a corticosteroid like dexamethasone, tocilizumab, or remdesivir.
- Related: WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge.
- "This result confirms and extends earlier findings, providing greater certainty that baricitinib is beneficial and new data to guide the treatment of COVID-19 patients with a combination of drugs to dampen the immune response," said Peter Horby, Oxford professor and joint chief investigator.
- In the RECOVERY trial, baricitinib also increased the chances of patients being discharged alive within 28 days and reduced the risk of their condition worsening, scientists said.
- Price Action: LLY shares are up 0.93% at $256.54, INCY shares are down 1.16% at $68.78 during the market session on the last check Thursday.
